Patient
SITE010-0248
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE010 (ESP) (Dr. Silva)
consented 2026-06-15
Adverse events
7
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 2 Neutropenia — outcome: UNKNOWN; onset 2023-03-05 (study day 70); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-15 (study day 52); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-02-04 (study day 41); relationship: RELATED
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-29 (study day 35); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-10 (study day 16); relationship: NOT RELATED
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-09 (study day 15); relationship: NOT RELATED
Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-02 (study day 8); relationship: RELATED; serious criteria: life-threatening
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.